Odypharm Limited

POWER SEARCH PRICING

SOLUTIONS

odypharm limited Company Information

Company Number

05458659

Next Accounts

100 days late

Directors

Santosh Deshpande

Gabriel Keita

View All

Shareholders

odypharm lifescience hong kong ltd

Group Structure

View All

Industry

Other business support service activities n.e.c.

Registered Address

1 princeton mews, 167-169 london road, kingston upon thames, surrey, KT2 6PT

Website

www.odypharm.org

odypharm limited Estimated Valuation

£8.2m

Pomanda estimates the enterprise value of ODYPHARM LIMITED at £8.2m based on a Turnover of £11.5m and 0.71x industry multiple (adjusted for size and gross margin).

Edit your figures and get a professional valuation report.

Odypharm Limited is a live company located in kingston upon thames, KT2 6PT with a Companies House number of 05458659. It operates in the other business support service activities n.e.c. sector, SIC Code 82990. Founded in May 2005, it's largest shareholder is odypharm lifescience hong kong ltd with a 100% stake. Odypharm Limited is a mature, mid sized company, Pomanda has estimated its turnover at £11.5m with declining growth in recent years.

View Sample

Upgrade for unlimited company reports & a free credit check

Pomanda's financial health check has awarded Odypharm Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 6 areas for improvement. Company Health Check FAQs

Health Rating3out of 5

3 Strong

2 Regular

6 Weak

Size

annual sales of £11.5m, make it larger than the average company (£3.1m)

Growth

3 year (CAGR) sales growth of -9%, show it is growing at a slower rate (4.1%)

EXPORT

Odypharm Limited's latest turnover from March 2023 is estimated at £11.5 million and the company has net assets of £404.4 thousand. According to their latest financial statements, Odypharm Limited has 5 employees and maintains cash reserves of £653.3 thousand as reported in the balance sheet.

Data source: Companies House, Pomanda Estimates

	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	May 2013	May 2012	May 2011	May 2010
Turnover	11,533,251	11,483,933	10,322,164	15,535,542	9,010,212	4,687,392	3,641,101	3,962,919	6,482,909	4,928,454	2,478,069	303,263	463,665	486,004
Other Income Or Grants
Cost Of Sales	7,069,134	7,124,403	6,472,313	9,625,576	5,607,450	2,279,124	1,771,130	2,057,721	4,103,875	3,141,735	1,587,636	189,739	281,221	288,237
Gross Profit	4,464,116	4,359,530	3,849,851	5,909,966	3,402,762	2,408,268	1,869,971	1,905,198	2,379,034	1,786,719	890,434	113,524	182,445	197,767
Admin Expenses	5,105,302	3,443,330	4,953,640	5,601,257	3,545,409	1,963,000	1,795,389	1,565,891	2,203,653	1,789,546	581,145	82,113	35,610	94,718
Operating Profit	-641,186	916,200	-1,103,789	308,709	-142,647	445,268	74,582	339,307	175,381	-2,827	309,289	31,411	146,835	103,049
Interest Payable
Interest Receivable	17,878	1,186	71	88	723				857	1,966	1,908	1,080	1,087	446
Pre-Tax Profit	-623,308	917,386	-1,103,718	308,796	-141,924	445,268	74,582	339,307	176,238	-861	311,197	32,491	147,922	103,494
Tax		-174,303		-58,671		-84,601	-14,736	-67,980	-37,010		-71,575	-7,798	-38,460	-28,978
Profit After Tax	-623,308	743,083	-1,103,718	250,125	-141,924	360,668	59,846	271,327	139,228	-861	239,622	24,693	109,462	74,516
Dividends Paid
Retained Profit	-623,308	743,083	-1,103,718	250,125	-141,924	360,668	59,846	271,327	139,228	-861	239,622	24,693	109,462	74,516
Employee Costs	223,836	211,263	200,833	198,870	192,839	181,824	177,824	178,276	1,810,959	1,375,425	697,736	110,651	144,394	142,882
Number Of Employees	5	5	5	5	5	5	5	5	51	39	19	3	4	4
EBITDA*	-604,267	938,757	-1,082,937	326,357	-114,012	459,831	105,900	356,845	181,903	-2,827	309,289	31,411	146,835	103,049

* Earnings Before Interest, Tax, Depreciation and Amortisation

	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	May 2013	May 2012	May 2011	May 2010
Tangible Assets	3,083	5,549				1,587	5,774	5,715	6,219
Intangible Assets	314,735	255,022	207,989	176,614	144,282	125,465	76,933	10,459	14,447
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets	317,819	260,572	207,989	176,614	144,282	127,053	82,708	16,174	20,666
Stock & work in progress								48,445	72,153
Trade Debtors	2,706,357	2,966,180	2,455,382	3,664,106	2,265,773	2,480,779	2,199,240	1,914,713	1,020,653	705,971	266,579	55,206	44,222
Group Debtors					73,953	16,742	41,594	328,878
Misc Debtors	123,341	76,499	37,254	49,689	129,376	87,666	115,069	128,768
Cash	653,279	188,049	128,159	13,704	162,046	30,638	63,649	198,815	144,054	198,872	587,689	175,577	256,533	178,199
misc current assets
total current assets	3,482,978	3,230,729	2,620,795	3,727,499	2,631,149	2,615,826	2,419,553	2,619,619	1,236,859	904,843	854,268	230,783	300,755	178,199
total assets	3,800,797	3,491,301	2,828,784	3,904,113	2,775,431	2,742,879	2,502,260	2,635,793	1,257,526	904,843	854,268	230,783	300,755	178,199
Bank overdraft
Bank loan
Trade Creditors	737,516	468,624	433,312	967,551	453,185	712,740	839,020	741,968	656,428	442,756	390,755	6,892	101,557	88,463
Group/Directors Accounts	2,252,133	1,577,163	1,765,092	1,139,710	871,993	564,650	661,049	325,803
other short term finances
hp & lease commitments
other current liabilities	406,736	417,795	345,440	408,367	312,006	185,317	40,315	675,276
total current liabilities	3,396,386	2,463,582	2,543,845	2,515,628	1,637,185	1,462,708	1,540,385	1,743,048	656,428	442,756	390,755	6,892	101,557	88,463
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities										1,395	1,450	1,450	1,450	1,450
provisions
total long term liabilities										1,396	1,450	1,450	1,450	1,450
total liabilities	3,396,386	2,463,582	2,543,845	2,515,628	1,637,185	1,462,708	1,540,385	1,743,048	656,428	444,152	392,205	8,342	103,007	89,913
net assets	404,411	1,027,719	284,939	1,388,485	1,138,246	1,280,171	961,876	892,745	601,098	460,690	462,063	222,441	197,748	88,286
total shareholders funds	404,411	1,027,719	284,939	1,388,485	1,138,246	1,280,171	961,876	892,745	601,098	460,690	462,063	222,441	197,748	88,286

	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018	Mar 2017	Mar 2016	Mar 2015	Mar 2014	May 2013	May 2012	May 2011	May 2010
Operating Activities
Operating Profit	-641,186	916,200	-1,103,789	308,709	-142,647	445,268	74,582	339,307	175,381	-2,827	309,289	31,411	146,835	103,049
Depreciation	2,466	1,850			1,586	3,934	15,660	1,797	250
Amortisation	34,453	20,707	20,852	17,648	27,048	10,629	15,658	15,741	6,272
Tax		-174,303		-58,671		-84,601	-14,736	-67,980	-37,010		-71,575	-7,798	-38,460	-28,978
Stock							-48,445	-23,708	72,153
Debtors	-212,982	550,044	-1,221,159	1,244,692	-116,084	229,284	-16,457	1,351,707	314,683	439,391	211,373	10,984	44,222
Creditors	268,892	35,312	-534,239	514,366	-259,555	-126,280	97,052	85,540	213,671	52,001	383,863	-94,665	13,094	88,463
Accruals and Deferred Income	-11,059	72,355	-62,927	96,361	126,689	145,002	-634,961	675,276
Deferred Taxes & Provisions
Cash flow from operations	-133,452	322,077	-458,944	-366,279	-130,795	164,668	-381,843	-278,318	-28,272	-390,217	410,204	-82,036	77,247	162,534
Investing Activities
capital expenditure	-94,166	-75,139	-52,227	-49,980	-45,864	-58,908	-97,851	-13,046	-27,188
Change in Investments
cash flow from investments	-94,166	-75,139	-52,227	-49,980	-45,864	-58,908	-97,851	-13,046	-27,188
Financing Activities
Bank loans
Group/Directors Accounts	674,970	-187,929	625,382	267,716	307,343	-96,399	335,246	325,803
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities									-1,395	-55				1,450
share issue		-304	172	113		-42,373	9,284	20,321	1,179	-512				13,770
interest	17,878	1,186	71	88	723				857	1,966	1,908	1,080	1,087	446
cash flow from financing	692,848	-187,047	625,625	267,917	308,066	-138,772	344,530	346,124	641	1,399	1,908	1,080	1,087	15,666
cash and cash equivalents
cash	465,230	59,890	114,455	-148,342	131,407	-33,010	-135,166	54,761	-54,818	-388,817	412,112	-80,956	78,334	178,199
overdraft
change in cash	465,230	59,890	114,455	-148,342	131,407	-33,010	-135,166	54,761	-54,818	-388,817	412,112	-80,956	78,334	178,199

Very Low Risk70 - 100

Low Risk50 - 70

Moderate Risk30 - 50

High Risk20 - 30

Very High Risk0 - 20

Get a comprehensive credit check for odypharm limited. Get real-time insights into odypharm limited's credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Perform a competitor analysis for odypharm limited by selecting its closest rivals, whether from the ADMINISTRATIVE AND SUPPORT SERVICE ACTIVITIES sector, other mid companies, companies in KT2 area or any other competitors across 12 key performance metrics.

ODYPHARM LIMITED group structure

Odypharm Limited has no subsidiary companies.

Ultimate parent company

ODYPHARM LIFESCIENCE HONG KONG LTD

#0074256

1 parent

ODYPHARM LIMITED

05458659

ODYPHARM LIMITED Shareholders

odypharm lifescience hong kong ltd

100%

Odypharm Limited currently has 6 directors. The longest serving directors include Ms Santosh Deshpande (Sep 2010) and Mr Gabriel Keita (May 2014).

officer	country	age	start	end	role
Ms Santosh Deshpande	India	54 years	Sep 2010	-	Director
Mr Gabriel Keita	United Kingdom	58 years	May 2014	-	Director
Miss Liberty Davey	United Kingdom	33 years	Jun 2015	-	Director
Ms Liberty O'Brien	United Kingdom	33 years	Jun 2015	-	Director
Brice Meilo	United Kingdom	41 years	Jul 2015	-	Director
Mr Luc Meilo	United Kingdom	72 years	Oct 2015	-	Director

P&L

March 2023

turnover

11.5m

operating profit

-641.2k

gross margin

38.8%

+1.96%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2023

net assets

404.4k

-0.61%

total assets

3.8m

+0.09%

cash

653.3k

+2.47%

net assets

Total assets minus all liabilities

Similar Companies

diaros trading limited

4.5

ifse group limited

information security forum limited

4.5

hull esteem consortium psp limited

pentland brands limited

3.5

company number

05458659

Type

Private limited with Share Capital

industry

82990 - Other business support service activities n.e.c.

incorporation date

May 2005

ultimate parent company

ODYPHARM LIFESCIENCE HONG KONG LTD

previous names

N/A

address

1 princeton mews, 167-169 london road, kingston upon thames, surrey, KT2 6PT

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to odypharm limited.

When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.

Click to start generating capital raising & share issue transactions for ODYPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.

odypharm limited Company Information

odypharm limited Estimated Valuation

odypharm limited Estimated Valuation

odypharm limited Estimated Valuation

Odypharm Limited Overview

Odypharm Limited Health Check

ODYPHARM LIMITED financials

odypharm limited Credit Report and Business Information

Odypharm Limited Competitor Analysis

odypharm limited Ownership

odypharm limited directors

odypharm limited company details

odypharm limited Charges & Mortgages

odypharm limited Capital Raised & Share Issues BETA

odypharm limited Companies House Filings - See Documents